Validated LC‐MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI‐0690 in Preclinical Target Site PK/PD Studies
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Wietse M Schouten und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Nitroimidazoles, Antiparasitic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Dioraphte, Swedish Research Council, Research Council United Kingdom Grand Challenges Research Funder.
Abstract (Originalsprache)
Understanding the target site pharmacokinetics (PK) of the nitroimidazole analog DNDI‐0690, a potential drug for the neglected parasitic disease leishmaniasis, is important due to the diversity of infected tissue sites and potential drug penetration variability. An ultrahigh‐performance liquid chromatography–tandem mass spectrometry (UHPLC‐MS/MS) method was developed and validated for quantifying DNDI‐0690 in murine biomatrices (plasma, liver, spleen, skin, and skin microdialysate). The method used three protein precipitation sample preparation procedures, tailored for different biomatrices, utilizing a surrogate biomatrix approach. Murine tissues were enzymatically homogenized with a Collagenase A mixture. Chromatographic detection was performed on a C18 column using gradient elution, coupled to a QTRAP6500 quadrupole MS, operating in positive ionization mode. The method demonstrated accurate and precise quantification of all murine biomatrices on the surrogate biomatrix calibration standards, with a high and reproducible total recovery ranging from 75.9% to 94.2% (CV% ≤ 2.5%). Matrix interferences were mitigated with a deuterated internal standard. Stability experiments demonstrated that DNDI‐0690 remained stable in all biomatrices under various conditions. This validated UHPLC‐MS/MS method was successfully used to quantify DNDI‐0690 in a target site murine infection model, demonstrating its suitability for future target site PK studies involving DNDI‐0690.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Skin Research Centre, Hull York Medical School, York Biomedical Research Institute, University of York, York, UK.
- Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
- Drugs for Neglected Diseases Initiative Latin America, Rio de Janeiro, Brazil.
ORCID-Profile: Wietse M Schouten
Förderung
- Stichting Dioraphte
- Swedish Research Council
- Research Council United Kingdom Grand Challenges Research Funder
- Vetenskapsrådet
Zitieren
APA
Schouten, W. M., van Bocxlaer, K., Rosing, H., Huitema, A. D. R., Beijnen, J. H., Kratz, J. M., Mowbray, C. E., & Dorlo, T. P. C. (2025). Validated LC‐MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI‐0690 in Preclinical Target Site PK/PD Studies. Biomedical Chromatography. https://doi.org/10.1002/bmc.70158
Vancouver
Schouten WM, van Bocxlaer K, Rosing H, Huitema ADR, Beijnen JH, Kratz JM, et al. Validated LC‐MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI‐0690 in Preclinical Target Site PK/PD Studies. Biomedical Chromatography. 2025. doi:10.1002/bmc.70158
BibTeX
@article{Schouten2025,
author = {Schouten, Wietse M and van Bocxlaer, Katrien and Rosing, Hilde and Huitema, Alwin D R and Beijnen, Jos H and Kratz, Jadel M and Mowbray, Charles E and Dorlo, Thomas P C},
title = {Validated LC‐MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI‐0690 in Preclinical Target Site PK/PD Studies},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70158}
}
EUVIMED